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The global political economy of stem cell therapies is characterised by an established biomedical he-
gemony of expertise, governance and values in collision with an increasingly informed health consumer
demand able to deﬁne and pursue its own interest. How does the hegemony then deal with the challenge
from the consumer market and what does this tell us about its modus operandi? In developing a theo-
retical framework to answer these questions, the paper begins with an analysis of the nature of the
hegemony of biomedical innovation in general, its close relationship with the research funding market,
the current political modes of consumer incorporation, and the ideological role performed by bioethics
as legitimating agency. Secondly, taking the case of stem cell innovation, it explores the hegemonic
challenge posed by consumer demand working through the global practice based market of medical
innovation, the response of the national and international institutions of science and their reassertion of
the values of the orthodox model, and the supporting contribution of bioethics. Finally, the paper ad-
dresses the tensions within the hegemonic model of stem cell innovation between the key roles and
values of scientist and clinician, the exacerbation of these tensions by the increasingly visible demands of
health consumers, and the emergence of political compromise.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Towhat extent does the rise of the active health consumer in the
globalised knowledge economy of the life sciences challenge the
hegemonic model of biomedical innovation propagated by the
developed countries of North America, Europe and Japan? Driven
by a supply side alliance of science, medicine and industry, that
model has assumed that consumer demand will wait passively for
the arrival of a supply of new health technologies through the
lengthy innovation process of basic research, clinical experimen-
tation, product development, clinical trials, product approval and
clinical application. This supply side approach works so long as the
authority of science andmedicine is able to control the operation of
the health care market by convincing consumers that their choice
of treatments should bewhat science andmedicine say they should
be: the demand side of the market is deemed to be the mirror
image of the supply side. Underpinning the orthodox model is annomy, King’s College London,
lter), yinhua.zhou@kcl.ac.uk
r Ltd. This is an open access articleasymmetry of knowledge between science and medicine, on the
one hand, and health consumers, on the other. Health consumers
do not need their own sources of information because, the logic
goes, the supply side is governed to ensure the protection of their
interests. Demand side governance through informed consumer
choice is therefore unnecessary.
Employing a political economy approach, this paper develops a
theoretical framework to analyse the extent to which such a he-
gemony of innovation values may be challenged when health
consumers question that authority, construct and analyse their own
knowledge sources and, critically, are able to access a supply of
health treatments delivered through an alternative model, or
models, of innovation based in the market of medical practice.
Under such conditions the demand side may be activated not only
in terms of an economic demand for what the orthodox model may
judge to be ‘illicit’ health care products but also a political demand
for a redeﬁnition of the innovation model itself, its rules and its
values. What constitutes legitimate innovation then becomes
problematic.
The political economy of the demand-supply relationship in
biomedical innovation and its implications for hegemony are
particularly visible in the ﬁeld of novel stem cell therapies. Here aunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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treatments for a wide range of conditions including spinal-
cordinjury, muscular dystrophy, optic nerve hypoplasia (ONH),
septo-optic dysplasia (SOD), Lyme Disease, diabetes, ataxia, cere-
bral palsy and Parkinson's disease connects easily to a global de-
mand from thousands of health consumers (Salter et al., 2014; Sipp,
2011). However, the operation of this market is restricted because
the model of stem cell innovation used by such clinics is rooted in
the domain of medical practice rather than that of scientiﬁc
research. Such practice based innovation is condemned as un-
proven, unsafe and illegitimate by supporters of the orthodox sci-
ence based model of stem cell innovation e itself able to generate
only a very limited supply of new therapies for a restricted range of
conditions e and consumers who purchase such stem cell therapy
products are dismissed as ill-informed ‘stem cell tourists’ (Dedmon,
2009; Ryan et al., 2010). International scientiﬁc organisations such
as the International Society for Stem Cell Research (ISSCR) warn
strongly against consumer use of the clinics (Baker, 2008). States
with an established tradition of regulation in orthodox biomedical
innovation look to tighten their rules to prevent or restrict their
operation (Fink, 2010). And bioethicists discuss how better to
protect what are assumed to be vulnerable health consumers from
exploitation by what are assumed to be mercenary clinicians
(Cohen and Cohen, 2010). Yet, despite this, consumer demand for
the stem cell therapy clinics continues to increase (Ogbogu et al.,
2013), the market for stem cells is projected to rise from $26
billion in 2011 to $119 billion in 2018 (Transparency Market
Research, 2013), and the hegemonic structures of the orthodox
model are beginning to look less than secure.
The dynamic of the global political economy of stem cell ther-
apies, where an established biomedical hegemony of expertise,
governance and values collides with an increasingly informed
health consumer demand able to deﬁne and pursue its own inter-
est, is thus well established. How does the hegemony then deal
with the challenge from the consumer market and what does this
tell us about its modus operandi? In developing a theoretical
framework to answer these questions, the paper begins with an
analysis of the major components of the hegemony of biomedical
innovation: the scientiﬁc paradigm that underpins it, the values
that legitimise it, the markets that sustain it and the national and
transnational institutions of governance that protect it. Secondly, it
examines the hegemonic challenge posed by consumer demand
working through the global practice based market of medical
innovation, the response of the national and international in-
stitutions of science to this emerging counter-hegemony and their
reassertion of the values of the orthodox model. Finally, the paper
addresses the resulting tensions within the hegemonic model of
stem cell innovation between the key roles and values of scientist
and clinician, the exacerbation of these tensions by the increasingly
visible demands of health consumers, and the political compro-
mises that are beginning to emerge.
2. Hegemony in biomedical innovation
In his essay on how Gramsci's concept of hegemony could be
adapted to promote understanding of the problems of world order,
Robert Cox argues that the Machiavellian connection in Gramsci's
work ‘frees the concept of power (and of hegemony as one form of
power) from a tie to historically speciﬁc social classes and gives it a
wider applicability to relations of dominance and subordination,
including… .relations of world order’ (Cox, 1983: 164). Although in
the period since Cox's seminal paper the concept has been applied
principally to the global hegemony of the United States and the
neo-liberal economy (see eg Beeson and Bell, 2009; Wade, 2002),
the applicability of its theoretical thrust to innovation in theknowledge economy of biomedicine, where the dominant innova-
tion model is driven by Western science and Western states, is
clear. Throughout the process of biomedical innovation from basic
research, through clinical experimentation and clinical trials, to
product approval and clinical application can be discerned the
operation of the main conceptual elements of Gramsci's analysis.
In this analysis the driving force of hegemony is the blocco
storico, the historical block and dominant group. More than simply
a political alliance between social forces, the blocco storico in-
tegrates and propagates a set of interests ‘bringing about not only a
unison of economic and political aims, but also intellectual and
moral unity… on a “universal” plane’ (Gramsci, 1971: 181e2). This
unity is achieved through the maintenance of a cultural hegemony
expressed in terms of:
‘Consent given by the great masses of the population to the
general direction imposed on social life by the dominant funda-
mental group; this consent is “historically” caused by the prestige
(and consequent conﬁdence) which the dominant group enjoys
because of its position and function in the world of production.’
(Gramsci, 1971: 145).
In biomedical innovation the blocco storico is biomedical sci-
ence: the agency deﬁning, owning and propagating the paradigm
governing the production of knowledge in this ﬁeld from the basic
science through to the clinical product. Underpinning the paradigm
are the organising values of science: objectivity, the importance of
the scientiﬁc method, and the discovery and application of gen-
eralisable principles of causality. The objective of biomedical sci-
ence, as with all science, is the advancement of knowledge within
the rule systems of the scientiﬁc method. This may beneﬁt citizens
and society but such beneﬁts are not the primary objective of sci-
entiﬁc activity. Hence in its Guidelines for the clinical translation of
stem cells the ISSCR is at pains to distinguish the activity of clinical
research which ‘aims to produce generalisable knowledge about
new cellular or drug treatments, or new approaches to surgery’
from that of medical innovation where ‘the main goal of innovative
care is to improve an individual patient's condition’ (International
Society for Stem Cell Research, 2008a: 15). The ISSCR is clear that
where there is any conﬂict between the two objectives, it is the
former that should take precedence. Scientiﬁc rigour should not be
sacriﬁced on the altar of patient beneﬁt.
Helping to sustain the legitimacy of the paradigm of biomedical
science are what Gramsci terms the ‘traditional intellectuals’ of the
hegemony who are ‘experts in legitimation’ (Gramsci, 1971: 9e10)
tasked with ‘the function of developing and sustaining the mental
images, technologies and organisations which bind together the
members of a class and of an historic bloc into a common identity
(Cox, 1983: 168). Acting in this role for biomedical innovation are
the bioethicists. Their task is to legitimise biomedical innovation
through a system of facts and values which, as Berger and Luckman
observe, ‘”explains” the institutional order by ascribing cognitive
validity to its objectivated meanings’ and ‘justiﬁes the institutional
order by giving a normative dignity to its natural imperatives’
(Berger and Luckman,1967: 119). It is no coincidence that the rise of
bioethics as an intellectual and political force with the capacity to
produce, organise and disseminate a moral economy of authorita-
tive governance values directly parallelled the expansion of
biomedical research from the 1970s onwards (Evans, 2002: Salter
and Salter, 2007). Initially driven by the tenets of American ‘prin-
ciplism’, bioethics had as its objective the task, as Albert Jonsen puts
it, of creating ‘the common coin of moral discourse’ in order to help
resolve cultural tensions created by medical scientiﬁc advance
(Jonsen, 1998: 333). Bioethics emerged because it was politically
useful and ‘met the need of public policy makers for a clear and
simple statement of the ethical basis for regulation of research’
(Jonsen, 1994, xvi, as quoted by Evans, 2000, 34). Similarly, in her
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many, Jasanoff notes the dawning recognition in all three political
systems of the risks and promises engendered by the multifaceted
advances in genetics and biotechnology and shows how ‘bioethics
offered the promise of bringing order and principle to domains
previously governed by irrational, emotive and unanalysed re-
actions.’ (2005: 171).
As the traditional intellectuals of biomedical science, bio-
ethicists act to further its ideological interests (Callahan, 2006;
Koch, 2006). Through the enunciation and application of a set of
principles, standardised rules are established that enable the
translation of differentmoral positions to a commonmetric capable
of facilitating, usually on a cost-beneﬁt basis, choices and decisions.
For the principles to operate efﬁciently, they must combine to
produce a system capable of commensuration (the discarding of
information), predictability and calculability: the characteristics of
a currency (Evans, 2000). In this sense bioethical debate can be seen
as a supporting forum for trading-off of values to facilitate and
legitimise the operation of the research funding market of science,
which we will discuss shortly. The two markets work in tandem
with the goal of maintaining the hegemony of biomedical innova-
tion. Whilst bioethics legitimises the values of the hegemony, in-
stitutions act to safeguard and enforce its rule systems. As with
Cox's portrayal of the neo-liberal hegemony, biomedicine works
through a world hegemony which is ‘expressed in universal norms,
institutions and mechanisms which lay down general rules of
behaviour for states and for those forces of civil society that act
across national boundaries e rules which support the dominant
mode of production’ (Cox, 1983: 172). Transnational scientiﬁc or-
ganisations and national regulatory bodies provide the institutional
vehicles for the dissemination of the Western model of biomedical
innovation, drawing on the ‘objective’ qualities of the scientiﬁc
method as their main source of legitimation. In parallel with the
operation of the neo-liberal hegemony, international institutions
perform an ideological role in helping to ‘deﬁne policy guidelines
for states and to legitimate certain institutions and practices at the
national level’ (Cox, 1983, 173). In stem cell innovation, that role
takes the form of guidance on the governance of the basic and pre-
clinical stages of stem cell innovation driven by the work of the UK
Stem Cell Bank, the International Stem Cell Forum (ISCF) and the
ISSCR. Through their links with national research funding agencies,
these organisations have constructed an international infrastruc-
ture for the governance of the basic stem cell science dealing with
both technical and ethical issues of standardisation (Eriksson and
Webster, 2008; Waldby and Salter, 2008).
A major task of the transnational governance of science by sci-
ence is to ensure that, in its support for biomedical innovation, the
funding market of basic life sciences research works within the
hegemonic assumptions of the biosciences community. This market
operates quite independently of the health care market through
which health consumer demands and preferences for the innova-
tion products may be subsequently expressed. Policy initiatives to
develop a new area of medicine or treatment regime for a particular
disease work through public and private research funding agencies
dependent, through the peer review system, on scientiﬁc expertise
for judgements regarding the allocation of research resources.
Although thismarket is obliged to respond to the stated priorities of
government, it does so within an epistemic framework driven by
the imperatives of a value system dedicated to the systematic
advancement of scientiﬁc discovery, not to the interests of the state
and its citizens. Much has been made of the alleged changes in the
practice of science in response to pressures from these interests,
seeing the changes as indicative of a fundamental shift from au-
tonomy to public responsiveness (Buchbinder, 1993; Gibbons et al.,
1994). However, others are more sceptical, suspecting that sciencemay be simply adapting the cosmetic portrayal of its activities to
the new ideological climate of accountability whilst retaining the
substance and control of its direction (Pestre, 2000; Shinn, 2002).
From the Gramscian perspective, it is to be expected that the
hegemony of biomedical innovation will to an extent adapt in
response to such pressures for change. This is what Gramsci terms
trasformismo e a ‘strategy of assimilating and domesticating
potentially dangerous ideas by adjusting them to the policies of the
dominant coalition’ (Cox, 1983: 166e7). Successful hegemonies are
those capable of recognising, responding to and, if necessary, ac-
commodating the challenge from rising power groups (Germain
and Kenny, 1998). Part of the contribution of nation states to the
maintenance of the global hegemony may be in enabling hege-
monic adaptation through negotiation and arbitration whilst
retaining its essential character and power relationships. The
adaptive capacity of a hegemony is a measure of its sophistication
and its durability.
Trasformismo of the hegemony has proved to be more necessary
as the innovation process moves from the realm of basic research to
its application in the clinical setting. In the case of UK biosciences,
the longstanding tension between state and science has most
recently found political expression in the debate surrounding the
‘translation’ of laboratory based research into health products
through efﬁcient commercialisation. Most notably, the Cooksey
Report A review of UK research funding concluded ‘that the UK is at
risk of failing to reap the full economic, health and social benefits
that the UK's public investment in health research should generate’
(the state interest) as a result of two key gaps. These are ‘translating
ideas from basic and clinical research into the development of new
products and approaches to treatment of disease and illness; and
implementing those new products and approaches into clinical
practice’ (Cooksey, 2006: 3). Policies to address the gaps were
subsequently implemented through the new institutional vehicles
of Biomedical Research Centres, the Academic Health Sciences
Centres, the Medical Research Council's (MRC) translational fund-
ing programmes (including one on translational stem cell research),
the joint MRC/Technology Strategy Board (TSB) Biomedical Catalyst
initiative and the TSB Catapult Programme (Dzau et al., 2010; MRC,
2014; TSB, 2014).
Although these kinds of state interventions employ the research
funding market as an instrument for reforming the nature of
biomedical innovation to render it more responsive to the state's
economic and social priorities, they do not, nor are they intended
to, challenge the power structures of the biomedical science he-
gemony. Rather, trasformismo requires a mode of adaptation that
works with the weave of those institutions to achieve a sensible
compromise between the interests of science and those of the state
in the pursuit of hegemony maintenance.
The hegemony's capacity for trasformismo is also evident in its
conception of the role of health consumers in the creation and
application of medical knowledge. Traditionally that role has been
seen as essentially passive with consumers accepting that their
role, and some would say duty, is to contribute to life sciences
research through participation in clinical experimentation and
trials and, when the research cycle is complete, receive the clinical
beneﬁts thus generated (Harris, 2005). Certainly the hegemonic
model does not expect them to engage in the agenda setting of
medical research nor to question either the scientiﬁc logic that
governs the sequence of basic research, clinical experimentation,
product development, clinical trial and product approval or the
lengthy timescale (10e15 years) required to complete it. That is
regarded as the task of those who exercise power in the orthodox
model of biomedical innovation: the scientiﬁc community, funding
agencies, government and industry who contribute to the several
stages of the innovation process.
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biomedical innovation, again driven by the state, is apparent in the
incorporation of health consumers into the institutions of medical
science through what has been termed ‘sponsored consumerism’.
This is a policy with a long and chequered history in the UK Na-
tional Health Service (NHS) where health consumers are given
various types of consultative and advisory roles but no real power
(Salter, 2003). Closely allied to this process of institutional inclusion
has been the creation of an apparatus of sponsored public partici-
pation by states aware that public trust in science can no longer be
assumed but that the legitimacy of science has to be politically
constructed to support its hegemonic position. Much of the debate
over how best to do this and so resolve the tensions between sci-
ence, the state and health consumers has understood these ten-
sions as matters of disputed facts, requiring either education of a
(deﬁcient) public to equip them with the correct, scientiﬁc, un-
derstanding of the issues, or engagement of an (informed) public to
achieve consensus through dialogue. Examples of the latter are
initiatives such as consensus conferences, citizens' juries, and
public debates such as the ‘GM Nation?’ debate (Irwin and Wynne,
1996; Rowe and Frewer, 2005). In the case of UK health research,
the creation of the Health Research Authority (HRA) in December
2011 ‘to promote and protect the interests of patients in health
research and to streamline the regulation of research’ (HRA, 2014),
working through a detailed public involvement strategy, brings
these elements together and establishes an institutional platform
for health consumer sponsorship with statutory backing from the
Care Act 2014.
Such techniques of institutional inclusion in the clinical research
domain of biomedical innovation allow health consumers to be
absorbed into the governing apparatus of the life sciences funding
market and obliged to work within the agreed hegemonic agenda
of science and state. The hegemony assumes the absence of any
interaction between health consumer demand and competition in
the research fundingmarket. Instead, the ‘demand’ for the products
of innovation is seen to originate in the systems of reimbursement,
primarily state and insurance funds, inwhich health consumers are
embedded. State and insurance organisations make choices on
behalf of health consumers. In the absence of any direct market
power in this domain, health consumers can only turn to the re-
sources of patient organisations e at best a weak form of political
power e to offset the established institutional dominance of sci-
ence and state (Baggott and Forster, 2008; Wood, 2000). Given this
situation, it would seem that the capacity of health consumers to
establish an effective counter-hegemony in biomedical innovation
is bound to be limited.
3. Consumer demand and the emerging counter-hegemony
Gramsci and Cox assume that for hegemony to be challenged
there must exist a counter-hegemony armed with the institutions,
intellectuals and the capacity to wage a ‘war of position’ to ‘un-
dermine the legitimacy of the dominant ideology’ (Lipsitz, 1988:
146). It is argued here that a global challenge to the hegemony of
biomedical innovation has indeed emerged in the case of stem cell
innovation but as much through the individualised mechanism of
the market as a vehicle for consumer choice as through the formal
interplay of institutions and ideas. Health consumers have begun to
question the hegemonic model economically, through the market
choice of health care products unapproved by the hegemony
(Deloitte Centre for Health Solutions, 2011; Bookman and
Bookman, 2007); politically, through organised political challenge
of the hegemonic model, such as in the case of AIDS patients
(Epstein, 1996); and, to a lesser extent, ideologically, through the
propagation of alternative narratives about the process ofinnovation (Woods and McCormack, 2013).
The origins of the challenge to the hegemony of biomedical
innovation lie partly in the nature of the research funding market
itself. Competition between the domains of science for limited
funding resources leads to an inﬂation of claims regarding what
investment in a particular domain will achieve. With states now
insisting that life sciences funding be linked to the productivity of
the ﬁeld and its economic and social beneﬁts (see eg Department
for Business, Innovation and Skills, 2011), science domains have
an incentive to argue that theirs can deliver faster and more efﬁ-
ciently than others. These statements then impact on health con-
sumer demand by creating expectations about the early availability
of the new treatment. A form of what has been termed ‘promissory
politics’ is thus created characterised by an inﬂationary spiral of
‘hype and hope’ with clinicians caught between the twin forces of
competitive science and expectant health consumers, in stem cell
science as elsewhere (Morrison, 2012; Murdoch and Scott, 2010).
The expression of this demand forms part of an expanding
global health care market for both established and new treatments
(Connell, 2011; Cortez, 2008; Kangas, 2010). As with other markets,
it has beneﬁtted from the liberalising effects of the free movement
of goods and services promoted under the auspices of the World
Trade Organization and its General Agreement on Trade in Services
(Smith, 2004; Smith et al., 2009). Supported by an enabling infra-
structure of affordable travel, facilitating agencies, internet based
advertising and information and investment by governments keen
to access foreign revenue, the global market for orthodox health
care has expanded rapidly with new suppliers particularly in
emerging economies such as India, China and Singapore (Deloitte,
2009) Established treatments span the full range of medical ser-
vices but most commonly include dental care, cosmetic surgery,
elective surgery, and fertility treatment (Lunt et al., 2011). Estimates
of the value of the global health consumer market range from
approximately 8 million cross-border patients generating a market
value of USD 24e40 billion per year (Patients Beyond Borders,
2013) to a market size of USD 60 billion (2007) and upwards
(Herrick, 2007; Deloitte, 2009).
The global market for established health care treatments con-
stitutes a model and infrastructure of service delivery readily
applicable to the provision of novel therapies. As such it has the
potential to act as a vehicle for counter-hegemonic development in
biomedical innovation in terms both process and legitimating
values. At the centre of the model is the informed health consumer
who assumes she/he has the right to make their own choices to buy
treatment in a health care market which is another form of mass
consumption. In so doing, they reﬂect on information about their
condition and appropriate treatment drawn from a wide range of
sources which include not only the formally approved outlets of
science and state but also the burgeoning information banks of the
internet (Sulik and Eich-Krohm, 2008). The latter has proved to be
particularly important to consumers of stem cell therapies given
that the advice of the national and transnational hegemonic in-
stitutions of biomedicine is hostile towards the stem cell therapy
clinics consumers often want to access (see eg ISSCR, 2008a;
Australian Stem Cell Centre, 2009). In their search for informa-
tion, such consumers regularly engage with the numerous inter-
active facets of the Web 2.0 architecture (social networking sites,
blogs, wikis, folksonomies, video sharing sites, hosted services,
Web applications and mashups) as do the supplying clinics (Chen
and Gottweis, 2013; Levine, 2010; Petersen et al., 2013). Their de-
mand is fuelled by the characteristics of a particular disease con-
dition, the proximity of pain and/or death, and the limits of local
treatment which generates a calculation of risks and beneﬁts with
its own internalist rationality and values. Such a subjective ratio-
nality may be at odds with the rationality of the external observer,
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demandwith limited responsiveness to negative information about
stem cell therapies and a high tolerance of health risk (Miller and
Joffe, 2009; Slevin et al., 1988). It cannot be assumed that such a
consumer demand will behave in a manner consistent with the
values and rationality of the hegemonic model of biomedical
innovation. The demand may display its own logic, dynamic and
direction. Supported by the internet's facilitation of the demand-
supply engagement, the demand acts to create a dynamic stem
cell therapy cybermarket operating separately and in parallel to the
world of orthodox medicine with its ﬁxed information sources,
rigid regulatory apparatuses, and static power groups.
The ability of health consumer demand for stem cell therapies to
ﬁnd and activate new sources of information and supply in the
absence of an adequate supply of new therapies from orthodox
stem cell science poses an economic challenge to the hegemonic
order of biomedical stem cell innovation. It does so through a
preparedness to accept the products of the practice-based model of
medical innovation employed by the stem cell clinic providers, a
model roundly denounced by supporters of the hegemonic model
of scientiﬁc innovation. The two models are informed by the con-
trasting values of medicine and science. Hence, whereas for the
former the goal is the beneﬁt of the individual patient, for the latter
the goal is scientiﬁcally generalisable results achieved through the
application of the scientiﬁc method (Lindvall and Hyun, 2009;
ISSCR, 2008b: 15). Embedded in practice, then, ‘Medical innova-
tion in cellular therapy may be viewed as the ethical and legitimate
use of non-approved cell therapy by qualiﬁed health care pro-
fessionals in their practice of medicine’ (Gunter, 2010: 966). The
treatment should be scientiﬁcally based and safe, but its efﬁcacy
does not have to be proven. For example, in the case of the inno-
vative use of stem cells in heart repair, Mathur and Martin argue
that ‘When potential clinical beneﬁt has been shown, safety is the
primary consideration that should determine further trials. An
understanding of the mechanism of beneﬁt is highly desirable yet
not necessary.’ (Mathur and Martin, 2004: 188).
Such an approach offends the fundamental scientiﬁc value that
causality should be understood in order that generalisable knowl-
edge may be produced and applied, a central feature of the hege-
monic model. Given this value position, it is unsurprising that the
national and transnational institutions of stem cell science take the
view that, whilst ‘Historically, many medical innovations have been
introduced into clinical practice without a formal clinical trials
process’, it should nonetheless only be used ‘in some very limited
cases’, ‘only in exceptional circumstances… .primarily for seriously
ill patients who lack good medical alternatives'and as a ‘one off’
(ISSCR, 2008b: 15; Australian Stem Cell Centre, 2009). In addition,
the ISSCR is clear that there is a distinction between ‘responsible
clinician-scientists’ providing this limited medical innovation and
medical innovation provided through ‘the commercial purveyance
of unproven stem cell interventions’ which it condemns (ISSCR,
2008b: 5). In other words, the use of the market to supply medi-
cal innovations in response to consumer demand is unacceptable.
For health consumers to assert that their demand should form part
of the process of innovation, rather than simply exist as a given
once the process is complete, is a therefore a perspective that has to
be rejected.
It is, nonetheless, a perspective that is gaining political as well as
economic traction. By activating medical innovation through the
registering of their demand in the market of medical practice, stem
cell health consumers have stepped outside the economic limits of
the hegemony (the research funding market and the customary
systems of reimbursement) and used their economic power to
begin to legitimise the clinician values (the primacy of care for the
patient) of those supplying the innovative therapies. With theimpetus established outside the geographical and ideological ter-
ritory of the hegemony, consumers whose ability to access stem cell
therapies within that territory has been frustrated by the rules of
the orthodox model have then begun to question its legitimacy e
as, for example, happened recently in Italy (Margottini, 2013). A
counter-hegemony is beginning to take shape as a market-based
consumer-oriented challenge has been matched by political chal-
lenge in the form of health consumers' assertion of their right to
help determine the nature of biomedical innovation. In taking this
path, stem cell consumers are joining the broader journey of health
activism which, following the example of HIV/AIDS activism
(Epstein, 1996; Levine, 1988), has challenged the lengthy and
exclusive nature of the orthodox model arguing for greater health
consumer choice and involvement throughout the innovation
process. Consumer groups such as women, disability groups, and
those with neuromuscular disease have questioned, and in some
cases rejected, the accepted right of medical science to be the sole
arbiter of the patient contribution to innovations in their own
treatment (Rodwin, 1994; Ruzek, 2007; Woods and McCormack,
2013). In France, parents of children with neuromuscular dystro-
phy took the initiative to create and set the innovation agenda of a
research infrastructure capable of addressing their children's
therapeutic needs (Rabeharisoa, 2003). So although the hegemonic
model by which new health therapies are researched and devel-
oped remains politically intact, numerous precedents have been
established for its underlying values and legitimacy to be chal-
lenged, changes proposed and a counter-hegemony established
(Rabeharisoa and Callon, 2002).
It is inevitable that the emergence of a counter-hegemony
should engage the interest of the hegemony's traditional in-
tellectuals, the bioethicists. For the most part, bioethicists have
responded by protecting the hegemonic paradigm of stem cell
innovation using a strategy of ethical exclusion rather than positive
engagement with counter-hegemony values. They have propagated
ostensibly neutral arguments which focus on the issues confronting
the hegemonic model in stem cell science within its own domain
whilst neglecting the ethical issues associated with market based
medical innovation (.Lysaght and Campbell, 2013). As a result,
much of the bioethical stem cell debate has centred on the moral
issues raised by the creation and destruction of human embryos in
the generation of human embryonic stem cells (hESCs) and the type
of governance arrangements that would deal with the issues whilst
allowing the science to advance (see eg Brown, 2013; Walters,
2004). The impact of this highly selective debate, often translated
through national bioethics committees into policy advice, is
apparent in the global emergence of standardised national policies
for dealing with the hESC issue with some adaptation to local
cultures (Salter and Salter, 2007).
This discursive marginalisation of medical innovation is justiﬁed
in terms of the importance of the full implementation of the sci-
entiﬁc method (medical innovation is unacceptable because it in-
cludes unknowns in the causality chain) coupled with a view of the
negative effects of the market mechanism in stem cell innovation.
As Paolo Blanco, a leading stem cell scientist puts it in an article in
Nature: ‘Claiming the right to market products ahead of proof of
efﬁcacy can only bring ineffective products to market, degrade
medicine and impoverish all except, perhaps, the fortunate sellers.’
(Blanco, 2013, our emphasis) In common with the global health
care market in general where ‘medical tourism’ is frequently seen
by bioethicists as ethically problematic (Johnston, 2010; Snyder
et al., 2010), stem cell consumers are assumed to be subject to
the naturally exploitative character of the market and incapable of
making their own informed choices. As Mason puts it: ‘Stem cell
tourism is undoubtedly a growing menace to vulnerable patients
and their care-givers, potentially inﬂicting physical, psychological
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(Mason, 2010: 684). And on the supply side, stem cell clinicians are
portrayed as ‘predators disguised as life-saving physicians’ driven
by proﬁt alone (Mason, 2010: 683; see also Cohen and Cohen,
2010). The remedy proposed is more supply side regulation of the
stem cell therapy market in order to protect the consumer, elimi-
nate the ‘rogue’ clinician provider and maintain the ascendancy of
the hegemonic model of stem cell innovation.
4. Hegemonic tensions and political compromise
The initial response of the hegemonic model of stem cell sci-
entiﬁc innovation to the economic challenge posed by the opera-
tion of consumer choice in the global stem cell therapy market has
been the reassertion of scientiﬁc values and the exclusion of
medical innovation from the agenda and the debate. The objective
has been the retention of the control of innovation within the
research funding market of the scientiﬁc community, supported by
the ideological dominance delivered by the moral economy of
bioethics, with the market of medical practice as a source of
innovation thus isolated and marginalised. Despite the initial suc-
cess of this strategy, there are tensions within the institutions of the
hegemonic order which threaten its long term stability and suggest
that political compromise, more trasformismo, is required.
An illustration of this tension comes from Patrick Taylor, a
member of the ISSCR Task Force on the Clinical Translation of Stem
Cells, who suggests a counter-narrative to that of the scientiﬁc
hegemony:
‘That innovative therapy can be, and continues to be, so posi-
tively transformative in the right circumstances, ought to make us
cautious, I think, about treating it as a presumptively ﬂawed and
inferior activity that requires the corrective guidance of the
research paradigm. Each is legitimate in a certain sphere; each has
different goals; and, as I shall argue, each has distinct oversight
needs.’ (Taylor, 2010: 286).
This sentiment is echoed by the International Society for
Cellular Therapy (ISCT) which maintains that medical innovation
has an equal status with science led innovation and that ‘There is a
place for both [medical and scientiﬁc] paradigms in the cell therapy
global community’ (Gunter, 2010: 966). Taking a broader view of
biomedical innovation, one that is inclusive of the demand side of
the stem cell therapy market, the ISCT argues that patients and
their families or partners ‘should have the right to seek treatment
for their diseases. No entity should withhold this fundamental right
unless there is a high probability of harm to the patient’ (Gunter,
2010: 966). Here, for the ﬁrst time, we see the primacy of the
health consumer in the formulation of stem cell innovation
governance expressed in terms of both citizen rights and consumer
access. Its ideological signiﬁcance for the hegemony is consider-
able: once consumer demand is accepted as an important value in
the debate, it leads to an analysis of the supply side where scientiﬁc
innovation and medical innovation are given equal weight and
assessed in terms of not only their scientiﬁc integrity but also their
ability to respond to health consumer demand. This, in turn, pre-
sents problems for key components of the hegemony: ﬁrstly, the
relationship between the innovation roles of scientist and clinician
and, secondly, how each relates to the changing role of the health
consumer.
Within the hegemonic model of biomedical innovation there
have always been tensions between the values and working as-
sumptions of scientist and clinician, between the competing ob-
jectives of the advancement of knowledge, on the one hand, and
care for the patient, on the other. In their exploration of these two
cultures using interviews with stem cell scientists and clinicians,
Cribb et al. note that ‘the normative structures produced by theinstitutions and organisations of the scientiﬁc and the clinical
construct different ethical spaces and role positions’ reinforced by
the institutional accountabilities to their respective, and quite
distinct, professional communities. Scientists are accountable to
the peer review mechanisms and hierarchies of science, clinicians
to the regulatory bodies of medical practice (2007: 353). Their ca-
pacity towork harmoniously together or to negotiate the resolution
of differences in their common pursuit of biomedical innovation is
therefore constrained by their separate professional re-
sponsibilities (Wainwright et al, 2006). For the health consumer,
the implication of these tensions between two key roles in the
hegemonic model is that their own role relationship with the
innovation process may be framed as ‘researcher-subject’, ‘clini-
cian-patient’, or, sometimes, both (Easter et al., 2006: 697). The
signiﬁcance of the clinician's medical values in the applied stages of
stem cell innovation is that this part of the hegemonic innovation
process is more likely to be responsive to the demands of health
consumers than if scientiﬁc values regarding the disinterested
pursuit of knowledge dominate the domain. It means there is a
tension between the public hegemonic narrative of scientiﬁc
innovation propagated by the professional and funding bodies of
science and the private reality of how translational research actu-
ally takes place once the stages of clinical experimentation and
clinical trials with patients are reached.
With clinicians within the hegemony already culturally inclined
to be more sympathetic to the health consumer perspective, states
increasingly aware that global markets provide their citizens with
options that render the timescale of the orthodox model uncon-
vincing, and health consumer activism in biomedical innovation a
growing political force, the pressures for change in the hegemonic
model of stem cell innovation are mounting. Resistance to change
comes primarily from the science, its infrastructure of research
funding, and its traditional intellectuals, the bioethicists. In this
situation it is inevitably the state which is the prime mover in the
search for hegemonic adaptation. As that search progresses, the
initial ideological shift has proved to be a move away from the
scientiﬁc requirement that a new therapy be judged safe and of
proven efﬁcacy and towards the requirement that it be safe and has
the possibility of efﬁcacy. Clearly this means a diminution in the
status and signiﬁcance of the scientiﬁc criterion that an under-
standing of the process of causality is a necessary condition of any
biomedical innovation.
Thus far states have approached the task of hegemony adapta-
tion by amendments to the national regulatory frameworks of
biomedical innovation, universally based on the orthodox scientiﬁc
model, with the goal of creating greater ﬂexibility in the respon-
siveness to health consumer demand through the earlier creation of
a supply of new therapies. For example, energised by its large in-
vestment in regenerative medicine of which stem cell science
forms a signiﬁcant part, Japan has revised its Pharmaceutical Affairs
Law to enable the conditional approval of potential therapies after
initial safety tests in order to deliver therapies that are deemed safe,
but perhaps ineffective, as quickly as possible to patients who do
not otherwise have access to treatment (METI, 2014). In the UK, the
Early Access to Medicines Scheme launched in April 2014 will
provide access to designated products several years before licenc-
ing for health consumers with life threatening or seriously debili-
tating conditions without adequate treatment options. Products
will be assessed on the basis of Phase I and/or Phase II data (ie ef-
ﬁcacy will not be proven) (Medicines and Healthcare Products
Regulatory Agency, 2014). And in the US, the Investigational New
Drugs procedures allow the use of ‘an investigational drug outside
of a clinical trial to treat a patient with a serious or immediately life-
threatening disease or condition who has no comparable or satis-
factory alternative treatment options’ (US Food and Drug
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to have reached the point in their development where efﬁcacy is
proven.
The very recent introduction of these reforms means that it is
too early to say how successful they will prove to be as a political
compromise between the hegemonic power of science in stem cell
innovation and the economic, political and ideological challenge
from the growing counter-hegemony of health consumers. Work-
ing as they do through the existing policy apparatus of the orthodox
hegemonic model of scientiﬁc innovation, such reforms are still
institutionally incongruent with two important governance do-
mains which reside outside it yet form part of the market dynamic
of stem cell therapies supplied through medical innovation: med-
ical practice and consumer demand. The former is governed
through the normal regulation of the professional standards of
medical practice by licencing bodies and medical malpractice laws;
the latter through the availability of comprehensive data regarding
the quality of the product to enable informed consumer choice.
Neither has been addressed by the reforms thus far, constrained as
these are by the policy borders of the hegemonic territory, though
the reforms proposed by Lord Satchi's Medical Innovation Bill
currently making its way through the UK Parliament suggest that
change may be imminent (UK Parliament, 2014).
5. Conclusions
Health consumers are able to challenge the hegemony of the
science-based paradigm of stem cell innovation though the exer-
cise of their demand in a global market of practice-based medical
innovation. Despite the global reach of biomedical science, its
ideological cadre of bioethicists acting as its traditional in-
tellectuals, its total dominance of the research funding market, its
extensive political network of transnational scientiﬁc institutions
and its established alliance with agencies of the state, in the case of
stem cell innovation the hegemony has proved fallible. A counter-
hegemony has begun to emerge in an economic territory over
which the hegemony has little control, where consumers are
geographically mobile, and where the demand-supply relationship
is engineered through an elusive system of internet-driven infor-
mation. As the counter-hegemony gains strength, so the collision in
biomedical innovation between the logic of consumer choice and
the logic of orthodox science becomes ever more apparent. Even
within its own territory the hegemony has suffered reverses as
states, impatient with the implacable adherence of science to its
values without apparent regard for those of medicine, have begun
to make regulatory changes to enable greater responsiveness to
health consumer need and so draw their citizens back within the
hegemonic boundaries.
In many ways, the biomedical innovation hegemony is static,
embedded in the fortress of professional and state institutions that
constitute its means of dominance, unable effectively to counter, or
perhaps perceive, the nature of the hegemonic challenge. Mean-
while, its traditional intellectuals, the bioethicists, have yet to offer
either a convincing analysis of the problem or a strategy to deal
with it. Medical innovation, though a common part of clinical
practice, is not regarded as a legitimate area of possible compro-
mise by the hegemony but rather as a territory whose procedures
offend the causality principles of the scientiﬁc method so central to
the hegemonic identity. On their side, stem cell health consumers
are pursuing their interests through an engagement with a global
market that exploits the information possibilities of the Web 2.0
architecture to the full and bypasses the hegemonic messages of
the institutions of stem cell science. As they do so, what might be
termed ‘political consumerism’ is emerging: a hybrid form of pol-
itics characterised by a combination of the institutionalised healthactivism of patient groups and the novel, spontaneous, internet-
based networks of health consumers, their relatives and friends.
In the face of these hegemonic tensions, a key political role in
any re-negotiation of the hegemony of stem cell innovation is that
of the clinician: an embedded feature of the hegemonic structure of
scientiﬁc biomedical innovation yet ideologically committed to the
interests of the health consumer. If the global market for stem cell
therapies supplied through practice based medical innovation
continues to expand, states sensitive to the loss of domestic mar-
kets this represents may take the view that the hegemony should
address the governance needs of the clinician's territory of medical
innovation, rather than continuing to exclude this territory on the
grounds that it is ideologically unacceptable to the rigorous tenets
of science. Such a course will be difﬁcult but necessary if the he-
gemony is not to be outﬂanked by a counter-hegemony where the
innovative capacities of the market respond to the increasingly
informed demand of the health consumer.
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